Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 5/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529926 | 0.87 | NCF1 (0.44) | NCF1SCDARSLC2A1 | |
| SCHEMBL5527506 | 0.86 | NCF1 (0.43) | NCF1SCDARSLC2A1 | |
| SCHEMBL5530302 | 0.86 | HRH3 (0.43) | ARHRH3TLR8TLR7TLR9 | |
| SCHEMBL5528104 | 0.86 | HRH3 (0.45) | NCF1SCDARHRH3SLC2A1 | |
| SCHEMBL8236219 | 0.85 | HRH3 (0.41) | ARHRH3TLR8TLR7TLR9 | |
| SCHEMBL5527453 | 0.83 | NCF1 (0.41) | NCF1SCDARSLC2A1TLR8 | |
| SCHEMBL5529449 | 0.83 | SOS1 (0.41) | SCDHRH3SLC2A1TLR8TLR7 | |
| SCHEMBL5532330 | 0.82 | HRH3 (0.48) | NCF1SCDARHRH3SLC2A1 | |
| SCHEMBL5521993 | 0.82 | NCF1 (0.46) | NCF1SCDARHRH3SLC2A1 | |
| SCHEMBL5521962 | 0.81 | SCN8A (0.43) | NCF1SCDAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | NCF1 2805/4885SCD 1710/4885AR 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.